- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00955773
A Study of the GSK MEK Inhibitor GSK1120212 and Everolimus in Cancer Subjects (Cancer)
November 7, 2017 updated by: GlaxoSmithKline
An Open-Label, Dose-Escalation, Phase IB II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of the MEK Inhibitor GSK1120212 in Combination With Oral Everolimus in Subjects With Solid Tumors
The purpose of this study is to determine the recommended dose and regimen for the orally administered MEK inhibitor GSK1120212 dosed in combination with everolimus in subjects with solid tumors.
The escalation part of the study will determine the MTD.
The combination will be further explored in the expansion part in subjects with metastatic pancreatic cancer.
In addition, subjects with KRAS mutant non-small cell lung cancer will be enrolled.
Study Overview
Detailed Description
MEK112110 is a dose-escalation, open-label study to determine the recommended dose and regimen for the orally administered MEK inhibitor GSK1120212 dosed in combination with everolimus in subjects with solid tumors.
This will be accomplished using a dose-escalation procedure starting at low doses of GSK1120212 and everolimus.
Dose escalation will continue based on predefined parameters until the maximum tolerated dose is identified.
The recommended doses and regimens will be selected based on the safety and pharmacokinetic profiles.
The clinical activity of GSK1120212 dosed in combination with everolimus will be explored further in an expansion cohort consisting of 20 subjects with metastatic pancreatic cancer.
In addition a substudy will be conducted in 40 subjects with KRAS-mutant non-small cell lung cancer.
Study Type
Interventional
Enrollment (Actual)
64
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Paris Cedex 20, France, 75970
- GSK Investigational Site
-
-
-
-
Tennessee
-
Nashville, Tennessee, United States, 37203
- GSK Investigational Site
-
-
Texas
-
San Antonio, Texas, United States, 78229
- GSK Investigational Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form.
- Age 18 years old or older and able to swallow oral medication.
- Performance Status score of 0 or 1 according to the Eastern Cooperative Oncology (ECOG) scale for Dose Escalation Cohort. Subjects with ECOG of 2 can be enrolled for expansion cohort.
- Tumor Type criteria as listed in the protocol
- Fasting glucose < 126mg/dL
- Male subjects must agree to use one of the contraception methods listed in the protocol.
- A female subject is eligible to participate if she is of non-childbearing potential, and if she is of childbearing potential she must use protocol defined contraception methods.
- Calcium phosphate product less than or equal to 4.0 mmol2/L2 (50 mg2/dL2)
- Adequate organ system function as defined below in the protocol.
Exclusion Criteria:
- Malignancies related to HIV or solid organ transplant.
- Primary malignant brain tumors.
- Chemotherapy, radiotherapy, or immunotherapy within 28 days (or 42 days for prior nitrosoureas or mitomycin C) prior to the first dose of GSK1120212. Chemotherapy regimens given continuously or on a weekly basis with limited potential for delayed toxicity are permitted with approval of a GSK Medical Monitor if dosing of that agent is terminated at least 14 days prior to the first dose of GSK1120212.
- Use of an investigational anti-cancer drug within 28 days or 5 half-lives, whichever is shorter preceding the first dose of GSK1120212 - as long as a minimum of 14 days has passed between the last dose of the prior investigational anti-cancer drug and the first dose of GSK1120212.
- Previous treatment with an mTOR inhibitor unless approved by GSK Medical Monitor.
- Previous treatment with GSK1120212.
- History of sensitivity to any of the study medications, or components thereof or a history of drug or other allergy that, in the opinion of the investigator or GSK Medical Monitor, contraindicates their participation.
- Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to the study drug, DMSO, or excipients. (To date there are no known FDA approved drugs chemically related to GSK1120212).
- Use of a prohibited medication (as defined in the protocol).
- Current use of anticoagulants (e.g. warfarin, heparin) at therapeutic levels within seven days prior to the first dose of GSK1120212. Low dose (prophylactic) low molecular weight heparin (LMWH) is permitted provided that subject's PT and PTT meet entry criteria. Subjects required therapeutic levels of LMWH must receive approval from GSK Medical Monitor and monitored appropriately as clinically indicated.
- Gastrointestinal disease predicted to interfere with absorption of an oral drug, systemic disease, major surgery, or social/psychological issues that in the opinion of investigators would jeopardize compliance with protocol.
- History of retinal vein occlusion (RVO) or central serous retinopathy (CSR).
- Predisposing factors to RVO including uncontrolled hypertension, uncontrolled diabetes, uncontrolled hyperlipidemia, and coagulopathy.
- Visible retinal pathology as assessed by ophthalmologic exam that is considered a risk factor for RVO or CSR.
- Intraocular pressure > 21mm Hg as measured by tonography.
- Glaucoma diagnosed within 1 month prior to study Day 1.
- Symptomatic or untreated leptomeningeal or brain metastases or spinal cord compression. Subjects previously treated for these conditions that are asymptomatic and off corticosteroids for at least two weeks are permitted. Subjects are not permitted to receive enzyme inducing anti-epileptic drugs (EIAEDs).
- Unresolved toxicity greater than common terminology criteria for adverse events (CTCAE) grade 1 from previous anti-cancer therapy except alopecia (if applicable) unless agreed to by a GSK Medical Monitor and the Investigator.
- History of acute coronary syndromes (including unstable angina), coronary angioplasty, or stenting within the past 24 weeks.
- QTc interval ≥ 480 msecs.
- Class II, III, or IV heart failure as defined by the New York Heart Association (NYHA) functional classification system.
- Pregnant or lactating female.
- History or active hepatitis B or C.
- History of HIV infection.
- Subjects on chronic antifungal therapy.
- Unwillingness or inability to follow the procedures outlined in the protocol.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NON_RANDOMIZED
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Group I
20 to 30 solid tumor subjects will be dosed with GSK1120212 in combination with everolimus to identify Maximum Tolerated Dose.
Subjects will continue on study drug until disease progression or withdraw consent.
|
Dose escalation will begin at low doses of GSK1120212 and everolimus, then gradually increase in future cohorts.
Dose escalation will continue until a recommended combination dose is identified.
The recommended combination dose will be used to treat pancreatic and lung cancer patients in later groups in this study.
|
EXPERIMENTAL: Group II
20 subjects with pancreatic cancer will receive the recommended dose identified in group I. Subjects will remain on study drug until disease progression or withdrawal from consent.
|
Dose escalation will begin at low doses of GSK1120212 and everolimus, then gradually increase in future cohorts.
Dose escalation will continue until a recommended combination dose is identified.
The recommended combination dose will be used to treat pancreatic and lung cancer patients in later groups in this study.
|
EXPERIMENTAL: Group III
Approximately 40 lung cancer subjects will receive the recommended dose identified in group I. Subjects will remain on study until disease progression or withdrawal of consent.
|
Dose escalation will begin at low doses of GSK1120212 and everolimus, then gradually increase in future cohorts.
Dose escalation will continue until a recommended combination dose is identified.
The recommended combination dose will be used to treat pancreatic and lung cancer patients in later groups in this study.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
AEs and changes in laboratory values and vital signs
Time Frame: 6 months
|
6 months
|
Response rate, CR + PR of GSK1120212 and everolimus in KRAS-mutant NSCLC.
Time Frame: 6 months
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Duration of response
Time Frame: 6 months
|
6 months
|
GSK1120212 and everolimus PK parameters following repeat-dose (Day 15) administration of GSK1120212 and everolimus, including AUC(0-tau), Ct, Cmax, tmax, and t1/2, data permitting
Time Frame: 6 months
|
6 months
|
Tumor response as defined by RECIST 1.1.
Time Frame: 6 months
|
6 months
|
CA 19-9 levels compared to radiological response, per RECIST 1.1, over time for each pancreatic cancer subject
Time Frame: 6 months
|
6 months
|
Population PK parameters, oral clearance and oral volume of distribution of GSK1120212 and everolimus will be determined. Dependant upon the final compartmental model describing GSK1120212 + everolimus, add. PK may also be estimated.
Time Frame: 6 months
|
6 months
|
Clinical benefit response rate CR+PR+SD greater than 4mos
Time Frame: 6 months
|
6 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
August 17, 2009
Primary Completion (ACTUAL)
November 8, 2011
Study Completion (ACTUAL)
November 8, 2011
Study Registration Dates
First Submitted
August 6, 2009
First Submitted That Met QC Criteria
August 6, 2009
First Posted (ESTIMATE)
August 10, 2009
Study Record Updates
Last Update Posted (ACTUAL)
November 9, 2017
Last Update Submitted That Met QC Criteria
November 7, 2017
Last Verified
November 1, 2017
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 112110
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cancer
-
Cellworks Group Inc.RecruitingCancer | Relapsed Cancer | Refractory CancerUnited States
-
University of Michigan Rogel Cancer CenterRecruitingCancer Liver | Cancer Brain | Cancer Head &Neck | Cancer PelvisUnited States
-
UNC Lineberger Comprehensive Cancer CenterHyundai Hope On WheelsRecruitingCancer | Pediatric Cancer | Survivorship | Cancer MetastaticUnited States
-
Vanderbilt-Ingram Cancer CenterNational Institutes of Health (NIH)Active, not recruitingAdvanced Cancer | Relapsed Cancer | Refractory CancerUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)CompletedStage III Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IV Gastric Cancer | Stage IVA Colorectal Cancer | Stage IVA Pancreatic Cancer | Stage IVB Colorectal Cancer | Stage IVB Pancreatic Cancer | Stage IIIA Gastric Cancer | Stage IIIB Gastric Cancer | Stage IIIC Gastric... and other conditionsUnited States
-
MiRXES Pte LtdRecruitingBreast Cancer | Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Esophageal Cancer | Ovarian Cancer | Prostate Cancer | Thoracic Cancer | Liver CancerSingapore
-
Sidney Kimmel Cancer Center at Thomas Jefferson...CompletedStage I Breast Cancer | Stage I Uterine Corpus Cancer | Stage II Uterine Corpus Cancer | Stage III Uterine Corpus Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage... and other conditionsUnited States
-
University of California, San FranciscoBristol-Myers Squibb; PfizerTerminatedStage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Stage IIIC Rectal Cancer | Metastatic Colorectal Adenocarcinoma | Metastatic Colon Adenocarcinoma | Metastatic Rectal Adenocarcinoma | Stage IIIA Colon Cancer | Stage IIIB Colon Cancer | Stage IIIC Colon Cancer | Stage IV Colon Cancer | Stage IV Rectal... and other conditionsUnited States
-
Massachusetts General HospitalNational Comprehensive Cancer NetworkCompletedGastric Cancer | Pancreatic Cancer | Esophageal Cancer | Rectal Cancer | Colon Cancer | Hepatobiliary CancerUnited States
-
Johns Hopkins UniversityNational Cancer Institute (NCI); National Institute on Minority Health and...Enrolling by invitationCancer | Advanced Cancer | End Stage Cancer | MalignancyUnited States
Clinical Trials on GSK1120212 plus everolimus
-
Novartis PharmaceuticalsTerminatedCancerFrance, United States, Netherlands, Canada, Taiwan, Korea, Republic of
-
Samsung Medical CenterCompletedSmall Cell Lung CancerKorea, Republic of
-
National Taiwan University HospitalNovartisUnknownMetastatic Breast CancerTaiwan
-
Fondazione IRCCS Istituto Nazionale dei Tumori,...Active, not recruitingWell Differentiated Pancreatic Endocrine TumorItaly
-
Restorbio Inc.Active, not recruitingRespiratory Tract InfectionsUnited States
-
University of California, San FranciscoNovartis Pharmaceuticals; Pediatric Brain Tumor Foundation; The Lilabean Foundation...RecruitingHigh Grade Glioma | Low-grade Glioma | Recurrent World Health Organization (WHO) Grade II GliomaUnited States
-
University of BolognaUnknownHeart Transplantation | Cytomegalovirus Infection | Cardiac Allograft VasculopathyItaly
-
University Hospital, BordeauxCompletedCarcinoma, Renal Cell | Malignant Advanced Solid TumorsFrance
-
National Cancer Institute (NCI)Active, not recruitingAdvanced Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Metastatic Malignant Neoplasm in the Liver | Unresectable Solid NeoplasmUnited States, Canada
-
Eisai Co., Ltd.Completed